新晋女首富“不卖水不卖房”，财富风口彻底转向

Core Viewpoint - The article highlights the rise of Zhong Huijuan as the new richest woman in China, with a wealth of 141 billion yuan, primarily due to the significant increase in the market value of Hansoh Pharmaceutical, which surged from approximately 90 billion to over 200 billion HKD this year, reflecting the booming biopharmaceutical sector [4][7]. Company Overview - Zhong Huijuan is the founder, chairman, and CEO of Hansoh Pharmaceutical, which has transitioned from a generic drug company to an innovative drug enterprise focusing on major disease treatments such as oncology and autoimmune diseases [6][7]. - The company went public on the Hong Kong Stock Exchange in June 2019, marking a significant milestone in its growth trajectory [6]. Financial Performance - Hansoh Pharmaceutical's market value increased dramatically this year, with a year-to-date stock price increase of over 100%, contributing to Zhong Huijuan's wealth growth of over 60 billion yuan compared to the previous year [7]. - The company recently secured a major deal with Roche for a CDH17-targeted antibody-drug conjugate, which includes an upfront payment of 80 million USD and potential milestone payments totaling up to 1.45 billion USD, indicating a lucrative revenue stream from this single drug [7]. Industry Context - The biopharmaceutical sector in China is experiencing a significant boom, with many companies in the innovative drug space seeing substantial increases in their valuations and stock prices [12][14]. - The total value of business development (BD) transactions in China's innovative drug sector reached 63.55 billion USD in the first half of the year, surpassing the total for the entire year of 2024, highlighting the sector's rapid growth and investment interest [14][15]. - The article notes a trend of increasing wealth among pharmaceutical entrepreneurs, with several individuals in the industry experiencing significant financial gains due to the favorable market conditions [12][14]. Market Dynamics - The article mentions a recent adjustment period for the innovative drug sector, with some leading companies experiencing notable stock price corrections, indicating potential volatility in the market despite the overall growth [15].